Phytol-based novel adjuvants in vaccine formulation: 2. Assessment of efficacy in the induction of protective immune responses to lethal bacterial infections in mice

Journal of Immune Based Therapies and Vaccines

Volumn 4, Issue , 2006, Pages

  Lim, So Yon ^a   Bauermeister, Adam ^a   Kjonaas, Richard A ^a   Ghosh, Swapan K ^a  

^a INDIANA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; BACTERIUM ANTIBODY; CYTOKINE; DITERPENOID; ESCHERICHIA COLI VACCINE; FREUND ADJUVANT; INTERLEUKIN 6; PHIS 01; PHYTOL; STAPHYLOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG FORMULATION; ENTEROBACTER INFECTION; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; FATALITY; FEMALE; IMMUNE RESPONSE; MOUSE; NONHUMAN; SEPTIC SHOCK; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

EID: 33750693040     PISSN: 14768518     EISSN: 14768518     Source Type: Journal    
DOI: 10.1186/1476-8518-4-5     Document Type: Article

References (26)

1. Hemrick TS, Havell EA, Horton JR, Orndorff PE: Host and bacterial factors involved in the innate ability of mouse macrophages to eliminate internalized unopsonized Escherichia coli. Infect Immun 2000, 68:125-32.
2. Takeda K, Kaisho T, Akira S: Toll-like receptors. Annu Rev Immunol 2003, 21:335-76.
3. Janeway CA Jr, Medzhitov R: Innate immune recognition. Annu Rev Immunol 2002, 20:197-216.
4. Bendelac A, Medzhitov R: Adjuvants of immunity: harnessing innate immunity to promote adaptive immunity. J Exp Med 2002, 195:F19-23.
5. Hoebe K, Janssen E, Beutler B: The interface between innate and adaptive immunity. Nat Immunol 2004, 5:971-74.
6. Gomez MI, Sordelli DO, Buzzola FR, Garcia VE: Induction of cell-mediated immunity to Stophylococcus aureus in the mouse mammary gland by local immunization with a live attenuated mutant. Infect Immun 2002, 63:1165-72.
7. Su S, Ward MM, Apicella MA, Ward RE: A nontoxic, idiotope vaccine against gram-negative bacterial infections. J Immunol 1992, 148:234-38.
8. Hopkins WJ, Gendron-Fitzpatrick A, McCarthy DO, Haine JE, Uehling DT: Lipopolysccharide-responder and nonresponder C3H mouse strains are equally susceptible to an induced Escherichia coli urinary tract infection. Infect Immun 1996, 64:1369-72.
9. Windbichler M, Echtenacher B, Hehlgans T, Jensenius JC, Schwaeble W, Mannel DN: Involvement of the lectin pathway of complement activation in antimicrobial immune defense during experimental septic peritonitis. Infect Immun 2004, 72(9):5247-52.
10. Berzofsky JA, Ahlers JD, Janik J, Morris J, Oh S, Terabe M, Belyakov IM: Progress on new vaccine strategies against chronic viral infections. J Clin Invest 2004, 114(4):450-62.
11. Petrovsky N, Aguilar JC: Vaccine adjuvants: Current state and future trends. Immunol Cell Biol 2004, 82(5):488-96.
12. Lim S-Y, Meyer M, Kjonaas RA, Ghosh SK: Phytol derivatives as novel adjuvants: I. Assessment of safety and efficacy during stimulation of humoral and cell-mediated immune responses. 2006 in press.
13. Wagenlehner E, Niemetz A, Naber G: Spectrum of pathogens and resistance to antibiotics in urinary tract infections and the consequences for antibiotic treatment: study of urology inpatients with urinary tract infections (1994-2001). Urologe A 2003, 42(1):13-25.
14. Chou T: Emerging infectious diseases and pathogens. Nurs Clin North Am 1999, 34(2):427-42.
15. Takahashi K, Fukada M, Kawai M, Yokochi T: Detection of lipopolysccharide (LPS) and identification of its serotype by an enzyme-linked immunosorbent assay (ELISA) using poly-L-lysine. J Immunol Methods 1992, 153:67-71.
16. Turner AK, Terry TD, Sack DA, Londono-Arcila P, Darsley MJ: Construction and characterization of genetically defined aro omp mutants of enterotoxigenic Escherichia coli and preliminary studies of safety and immunogenicity in humans. Infect Immun 2001, 69(8):4969-79.
17. Hall AE, Domanski PJ, Patel PR, Vernachio JH, Syribeys PJ, Gorovits EL Johnson AM, Ross JM, Hutchins JT, Patti JM: Characterization of a protective monoclonal antibody recognizing Staphylococcus aureus MSCRAMM protein clumping factor A. Infect Immun 2003, 71:6864-6870.
18. Sasaki S, Nishikawa S, Miura T, Mizuki M, Yamada K, Madarame H, Tagawa Y-I, Iwakura Y, Nakane A: Interleukin-4 and interleukin-10 are involved in host resistance to Staphylococcus aureus infection through regulation of gamma interferon. Infect Immun 2000, 68(5):2424-2430.
19. Takano M, Nishimura H, Kimura Y, Mokuno Y, Washizu J, Itohara S, Nimura Y, Yoshikai Y: Protective roles of γδ T cells and interleukin-15 in Escherichia coli infection in mice. Infect Immun 1998, 66:3270-78.
20. Reid RR, Prodeus AP, Khan W, Hsu T, Rosen FS, Carroll MC: Endotoxin shock in antibody-deficient mice: unraveling the role of natural antibody and complement in the clearance of lipopolysaccharide. J Immunol 1997, 159:970-75.
21. Schiff DE, Wass CA, Cryz SJ Jr, Cross AS, Kim KS: Estimation of protective levels of anti-O-specific lipopolysccharide immunoglobulin G antibody against experimental Escherichia coli infection. Infect Immun 1993 61:975-980.
22. Michaelsen TE, Kolberg J, Aase A, Herstad TK, Hoiby EA: The four mouse IgG isotypes differ extensively in bactericidal and opsonophagocytic activity when reacting with the P1.16 epitope on the outer membrane PorA protein of Neisseria meningitidis. Scand J Immunol 2004, 59(1):34-9.
23. Dalrymple SA, Slattery R, Aud DM, Krishna M, Lucian LA, Murray R: Interleukin-6 is required for a protective immune response to systemic Escherichia coli infection. Infect Immun 1996, 64:3231-35.
24. Nakane A, Okamoto M, Asano M, Kohanawa M, Minagawa T: Endogenous gamma interferon, tumor necrosis factor, and interleukin-6 in Staphylococcus aureus infection in mice. Infect Immun 1995, 63:1165-72.
25. Tracy KJ, Fong Y, Hesse DG, Manogue HR, Lee AT, Kuo HC, Kuo GC, Lowry SF, cerami A: Anti-cachectin/TNF monoclonal anti-bodies prevent septic shock during lethal bacterimia. Nature 1987, 330:662-4.
26. Kaijser B, Ahlstedt S: Protective capacity of antibodies against Escherichia coli O and K antigens. Infect Immmun 1975, 17:286-89.